175 related articles for article (PubMed ID: 32735903)
1. Ultra-Response to Ranibizumab: Improvement by 4 or More Steps in Diabetic Retinopathy Severity in Diabetic Retinopathy Clinical Research Network Protocol S.
Chiang A; Garg SJ; Klufas MA; Ho AC; Hill L; Tsuboi M; Stoilov I
Ophthalmol Retina; 2021 Mar; 5(3):251-260. PubMed ID: 32735903
[TBL] [Abstract][Full Text] [Related]
2. The Clinical Importance of Changes in Diabetic Retinopathy Severity Score.
Ip MS; Zhang J; Ehrlich JS
Ophthalmology; 2017 May; 124(5):596-603. PubMed ID: 28284785
[TBL] [Abstract][Full Text] [Related]
3. Change in Diabetic Retinopathy Through 2 Years: Secondary Analysis of a Randomized Clinical Trial Comparing Aflibercept, Bevacizumab, and Ranibizumab.
Bressler SB; Liu D; Glassman AR; Blodi BA; Castellarin AA; Jampol LM; Kaufman PL; Melia M; Singh H; Wells JA;
JAMA Ophthalmol; 2017 Jun; 135(6):558-568. PubMed ID: 28448655
[TBL] [Abstract][Full Text] [Related]
4. Visual and Anatomic Outcomes in Patients with Diabetic Macular Edema with Limited Initial Anatomic Response to Ranibizumab in RIDE and RISE.
Pieramici DJ; Wang PW; Ding B; Gune S
Ophthalmology; 2016 Jun; 123(6):1345-50. PubMed ID: 26992841
[TBL] [Abstract][Full Text] [Related]
5. Long-term effects of ranibizumab on diabetic retinopathy severity and progression.
Ip MS; Domalpally A; Hopkins JJ; Wong P; Ehrlich JS
Arch Ophthalmol; 2012 Sep; 130(9):1145-52. PubMed ID: 22965590
[TBL] [Abstract][Full Text] [Related]
6. Effect of Aflibercept on Diabetic Retinopathy Severity and Visual Function in the RECOVERY Study for Proliferative Diabetic Retinopathy.
Alagorie AR; Velaga S; Nittala MG; Yu HJ; Wykoff CC; Sadda SR
Ophthalmol Retina; 2021 May; 5(5):409-419. PubMed ID: 32882447
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of Ranibizumab in Eyes with Diabetic Macular Edema and Macular Nonperfusion in RIDE and RISE.
Reddy RK; Pieramici DJ; Gune S; Ghanekar A; Lu N; Quezada-Ruiz C; Baumal CR
Ophthalmology; 2018 Oct; 125(10):1568-1574. PubMed ID: 29752001
[TBL] [Abstract][Full Text] [Related]
8. Durability of Diabetic Retinopathy Improvement with As-Needed Ranibizumab: Open-Label Extension of RIDE and RISE Studies.
Sun JK; Wang PW; Taylor S; Haskova Z
Ophthalmology; 2019 May; 126(5):712-720. PubMed ID: 30419298
[TBL] [Abstract][Full Text] [Related]
9. Early and Long-Term Responses to Anti-Vascular Endothelial Growth Factor Therapy in Diabetic Macular Edema: Analysis of Protocol I Data.
Gonzalez VH; Campbell J; Holekamp NM; Kiss S; Loewenstein A; Augustin AJ; Ma J; Ho AC; Patel V; Whitcup SM; Dugel PU
Am J Ophthalmol; 2016 Dec; 172():72-79. PubMed ID: 27644589
[TBL] [Abstract][Full Text] [Related]
10. Long-term effects of therapy with ranibizumab on diabetic retinopathy severity and baseline risk factors for worsening retinopathy.
Ip MS; Domalpally A; Sun JK; Ehrlich JS
Ophthalmology; 2015 Feb; 122(2):367-74. PubMed ID: 25439595
[TBL] [Abstract][Full Text] [Related]
11. Effect of less aggressive treatment on diabetic retinopathy severity scale scores: analyses of the RIDE and RISE open-label extension.
Goldberg RA; Hill L; Davis T; Stoilov I
BMJ Open Ophthalmol; 2022 Jul; 7(1):. PubMed ID: 36161830
[TBL] [Abstract][Full Text] [Related]
12. Effect of Adding Dexamethasone to Continued Ranibizumab Treatment in Patients With Persistent Diabetic Macular Edema: A DRCR Network Phase 2 Randomized Clinical Trial.
Maturi RK; Glassman AR; Liu D; Beck RW; Bhavsar AR; Bressler NM; Jampol LM; Melia M; Punjabi OS; Salehi-Had H; Sun JK;
JAMA Ophthalmol; 2018 Jan; 136(1):29-38. PubMed ID: 29127949
[TBL] [Abstract][Full Text] [Related]
13. Real-Time Photographic- and Fluorescein Angiographic-Guided Management of Diabetic Retinopathy: Randomized PRIME Trial Outcomes.
Yu HJ; Ehlers JP; Sevgi DD; Hach J; O'Connell M; Reese JL; Srivastava SK; Wykoff CC
Am J Ophthalmol; 2021 Jun; 226():126-136. PubMed ID: 33529593
[TBL] [Abstract][Full Text] [Related]
14. CHANGES IN DIABETIC RETINOPATHY SEVERITY WHEN TREATING DIABETIC MACULAR EDEMA WITH RANIBIZUMAB: DRCR.net Protocol I 5-Year Report.
Bressler SB; Odia I; Glassman AR; Danis RP; Grover S; Hampton GR; Jampol LM; Maguire MG; Melia M
Retina; 2018 Oct; 38(10):1896-1904. PubMed ID: 30234859
[TBL] [Abstract][Full Text] [Related]
15. Baseline Diabetic Retinopathy Severity and Time to Diabetic Macular Edema Resolution with Ranibizumab Treatment: A Meta-Analysis.
Talcott KE; Valentim CCS; Hill L; Stoilov I; Singh RP
Ophthalmol Retina; 2023 Jul; 7(7):605-611. PubMed ID: 36774994
[TBL] [Abstract][Full Text] [Related]
16. Impact of baseline Diabetic Retinopathy Severity Scale scores on visual outcomes in the VIVID-DME and VISTA-DME studies.
Staurenghi G; Feltgen N; Arnold JJ; Katz TA; Metzig C; Lu C; Holz FG;
Br J Ophthalmol; 2018 Jul; 102(7):954-958. PubMed ID: 29051325
[TBL] [Abstract][Full Text] [Related]
17. Rationale and Application of the Protocol S Anti-Vascular Endothelial Growth Factor Algorithm for Proliferative Diabetic Retinopathy.
Sun JK; Glassman AR; Beaulieu WT; Stockdale CR; Bressler NM; Flaxel C; Gross JG; Shami M; Jampol LM;
Ophthalmology; 2019 Jan; 126(1):87-95. PubMed ID: 30096354
[TBL] [Abstract][Full Text] [Related]
18. Enhanced Benefit in Diabetic Macular Edema from AKB-9778 Tie2 Activation Combined with Vascular Endothelial Growth Factor Suppression.
Campochiaro PA; Khanani A; Singer M; Patel S; Boyer D; Dugel P; Kherani S; Withers B; Gambino L; Peters K; Brigell M;
Ophthalmology; 2016 Aug; 123(8):1722-1730. PubMed ID: 27236272
[TBL] [Abstract][Full Text] [Related]
19. Impact of Cataract Surgery during Treatment with Ranibizumab in Patients with Diabetic Macular Edema.
Moshfeghi AA; Shapiro H; Lemmon LA; Gune S
Ophthalmol Retina; 2018 Feb; 2(2):86-90. PubMed ID: 31047350
[TBL] [Abstract][Full Text] [Related]
20. Ranibizumab Induces Regression of Diabetic Retinopathy in Most Patients at High Risk of Progression to Proliferative Diabetic Retinopathy.
Wykoff CC; Eichenbaum DA; Roth DB; Hill L; Fung AE; Haskova Z
Ophthalmol Retina; 2018 Oct; 2(10):997-1009. PubMed ID: 31047503
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
